SPAGO — Spago Nanomedical AB (publ) Share Price
Last trade - 00:00- SEK75.21m
- SEK42.74m
- SEK1.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.26 | ||
| Price to Tang. Book | 2.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 39.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -99.98% | ||
| Return on Equity | -87.21% | ||
| Operating Margin | -1764.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.34 | 0.66 | 1.05 | 1.2 | 1.91 | 9 | 14 | 129.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Spago Nanomedical AB (publ), formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. The Company is a nanomedicine company in clinical development phase, developing products for diagnostics and treatment of life-threatening and debilitating diseases. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The Company’s operations are based on a patented material for the design of functional nanoparticles that accumulate physiologically in tumors, thus enabling higher precision in image diagnostics and treatment of cancer and other severe diseases.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 18th, 1999
- Public Since
- January 15th, 2013
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 348,196,206
- Address
- Scheelevagen 22, LUND, 223 63
- Web
- https://spagonanomedical.se/
- Phone
- +46 4681188
- Auditors
- BDO Malardalen AB
Upcoming Events for SPAGO
Similar to SPAGO
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 23:22 UTC, shares in Spago Nanomedical AB (publ) are trading at SEK0.22. This share price information is delayed by 15 minutes.
Shares in Spago Nanomedical AB (publ) last closed at SEK0.22 and the price had moved by -39.66% over the past 365 days. In terms of relative price strength the Spago Nanomedical AB (publ) share price has underperformed the FTSE Global All Cap Index by -41.18% over the past year.
There is no consensus recommendation for this security.
Find out moreSpago Nanomedical AB (publ) does not currently pay a dividend.
Spago Nanomedical AB (publ) does not currently pay a dividend.
Spago Nanomedical AB (publ) does not currently pay a dividend.
To buy shares in Spago Nanomedical AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.22, shares in Spago Nanomedical AB (publ) had a market capitalisation of SEK75.21m.
Here are the trading details for Spago Nanomedical AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: SPAGO
Based on an overall assessment of its quality, value and momentum Spago Nanomedical AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Spago Nanomedical AB (publ) is SEK1.00. That is 362.96% above the last closing price of SEK0.22.
Analysts covering Spago Nanomedical AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Spago Nanomedical AB (publ). Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +1.75%.
As of the last closing price of SEK0.22, shares in Spago Nanomedical AB (publ) were trading -10.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Spago Nanomedical AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Spago Nanomedical AB (publ)'s directors